Latest Prostate Cancer News
Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.
In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.
Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.
Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.
Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.
Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.
The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.
Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.
Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.
Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.
Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)